<DOC>
	<DOCNO>NCT02967692</DOCNO>
	<brief_summary>To evaluate safety efficacy combination anti-PD-1 antibody ( PDR001 ) , BRAF inhibitor ( dabrafenib ) MEK inhibitor ( trametinib ) unresectable metastatic BRAF V600 mutant melanoma</brief_summary>
	<brief_title>A Study Anti-PD1 Antibody PDR001 , Combination With Dabrafenib Trametinib Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Inclusion criterion Part 1 : Safety runin Histologically confirm , unresectable metastatic melanoma BRAF V600 mutation Aspartate transaminase ( AST ) &lt; 2.5× ULN Alanine transaminase ( ALT ) &lt; 2.5× ULN ECOG performance status ≤ 1 Part 2 : Biomarker cohort Histologically confirm , unresectable metastatic melanoma BRAF V600 mutation At least two cutaneous subcutaneous nodal lesion tumor sample collection ECOG performance status ≤ 2 Part 3 : Doubleblind , randomize , placebocontrolled part Histologically confirm , unresectable metastatic melanoma BRAF V600 mutation ECOG performance status ≤ 2 Part 1 : Safety runin Subjects uveal mucosal melanoma Any history CNS metastases Prior systemic anticancer treatment unresectable metastatic melanoma Prior locoregional treatment unresectable metastatic melanoma last 6 month Prior neoadjuvant and/or adjuvant therapy melanoma complete less 6 month Radiation therapy within 4 week prior start study treatment Active , know , suspect documented history autoimmune disease Parts 2 &amp; 3 : Biomarker cohort &amp; doubleblind , randomize , placebocontrolled part Subjects uveal mucosal melanoma Clinically active cerebral melanoma metastasis Prior systemic anticancer treatment unresectable metastatic melanoma Prior locoregional treatment unresectable metastatic melanoma last 6 month Prior neoadjuvant and/or adjuvant therapy melanoma complete less 6 month Radiation therapy within 4 week prior start study treatment Active , know , suspect documented history autoimmune disease Other protocoldefined Inclusion/Exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PDR001</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>trametinib</keyword>
	<keyword>melanoma</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>PD 1 inhibitor</keyword>
	<keyword>anti PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>anti-PD-1</keyword>
	<keyword>combination treatment</keyword>
	<keyword>malignant skin cancer</keyword>
	<keyword>skin cancer</keyword>
	<keyword>BRAF V600</keyword>
	<keyword>unresectable BRAF V600 mutate melanoma</keyword>
	<keyword>metastatic BRAF V600 mutate melanoma</keyword>
</DOC>